Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21225242 | 0.84 | OPRM1 (0.33) | OPRM1OPRL1SLC6A9 | |
| SCHEMBL1762490 | 0.82 | CRBN (0.43) | CRBNDDB1NPSR1HPGDMAPK1 | |
| SCHEMBL21225419 | 0.80 | OPRM1 (0.32) | OPRM1OPRL1SLC6A9 | |
| SCHEMBL21225215 | 0.80 | ALDH1A1 (0.32) | HPGDALDH1A1 | |
| SCHEMBL21225699 | 0.77 | — | — | |
| SCHEMBL21225539 | 0.77 | JAK3 (0.33) | OPRM1OPRL1SLC6A9 | |
| SCHEMBL21238732 | 0.74 | GRIN2B (0.46) | MAPK1MEN1KMT2A | |
| SCHEMBL21238930 | 0.74 | POLB (0.32) | ALDH1A1 | |
| SCHEMBL21225675 | 0.73 | SLC6A9 (0.44) | CRBNDDB1OPRM1OPRL1SLC6A9 | |
| SCHEMBL21225358 | 0.72 | OPRM1 (0.33) | OPRM1OPRL1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047324-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047324-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | CRBN 3123/4885DDB1 2886/4885NPSR1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.